22nd January
We were absolutely delighted to be featured in S&P Global last week in an article written by Joseph Harvey. See the article covering this exciting business update below.
Posts about Halt Study:
TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)
25th June
We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was...
Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA
28th July
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our novel,...
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
28th July
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations You can read the full article below....
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
20th April
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
3rd February
Dr. Joshua Sterns presentation from VMX 2023
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
1st October
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway
14th September
TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM)...
TriviumVet advance their first feline product, a potential treatment for HCM in cats
21st January
TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned...
Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA
28th July
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our novel,...
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
28th July
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations You can read the full article below....
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
20th April
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
3rd February
Dr. Joshua Sterns presentation from VMX 2023
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
1st October
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway
14th September
TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM)...
TriviumVet advance their first feline product, a potential treatment for HCM in cats
21st January
TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned...